All News
ACR 2022 - Day 1 Report
The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.
Read Article
Ma et al. Calprotectin differentiates remission and low disease activity in RA. @RheumNow #ACR22 Abstr#0884 https://t.co/z9oeKPLq5z https://t.co/YFkIBEqT0c
Richard Conway RichardPAConway ( View Tweet)
Sarilumab in GC resistant PMR
🔥SAPHYR🔥
👉Arm 1- sar 200mg Q2W + 14wk GC
👉 Arm 2- PBO Q2W + 52wk GC
🌟RESULTS🌟
💪🏻 Arm 1 - PMR symp + signs ⬇️ wk 2 with continued improvement until wk 52
🌟Arm 1- ⬇️ chance flare post achieving remission
#ACR22 @RheumNow https://t.co/tXQuuoAelP
Patricia Harkins DrTrishHarkins ( View Tweet)
CLE to SLE transition occurred more frequently in pts aged 40 and younger, w/in the first 10 years of dx, and those with SCLE. Abs 0338 #ACR22 @RheumNow https://t.co/XxHjkNL5Hf https://t.co/1WtgmVM7Iz
Dr. Rachel Tate uptoTate ( View Tweet)
Saxena et al Zetomipzomib, a selective immunoproteasome inhibitor in lupus nephritis. Phase 2 study. UPCR=<0.5 achieved 64.7% week 37, pred=<10mg/day 82.4% week 13. @RheumNow #ACR22 Abstr#0992 https://t.co/askpmqsYYG https://t.co/cKoR0bgtWt
Richard Conway RichardPAConway ( View Tweet)
Wallace @zach_wallace_md et al. IgG4-RD in USA. Incidence 1.2/100,000, prevalence 2.8/100,000. Pancreas (43.0%), biliary tract (30.6%), salivary glands (11.7%), retroperitoneum (5.0%). HR 2.51 for mortality in IgG4-RD. @RheumNow #ACR22 Abstr#0713 https://t.co/IpjSKxmHQN
Richard Conway RichardPAConway ( View Tweet)
Opioid use in adults with PsA and AS
Abstract #0402 @RheumNow #ACR22
✋828 PsA patients ➡️ 21% used opioids
🦴 334 AS patients ➡️ 27% used opioids
💊Opioid users had more comorbidities, more medical visits, worse disease activity, and higher prevalence of 🚬
Catherine Sims, MD DrCassySims ( View Tweet)
Manansala et al. Baseline lymphopenia negatively predicts disease severity in sarcoid. It is protective for decline in FBC. @RheumNow #ACR22 Abstr#0830 https://t.co/Q4fE9LoG9L https://t.co/Tt1PyYLfWu
Richard Conway RichardPAConway ( View Tweet)
Ross et al. Comorbid liver disease significantly attenuates CRP rise with disease flare. Increased BMI increases CRP rise. @RheumNow #ACR22 Abstr#0811 https://t.co/O3PsDfbCMV https://t.co/9xAqWTJqkf
Richard Conway RichardPAConway ( View Tweet)
Fat and bone health are related via adipokines (fat hormones).
Data from VA registry of RA pts:
clear relationship between elevated adipokines & osteoporotic fracture risk.
This is why body fat should be a target for osteoporosis management
ABST0889 @PennRheum #ACR22 @RheumNow https://t.co/BoP8d4sooZ
David Liew drdavidliew ( View Tweet)
Vural et al Rituximab biosimilar switch in GPA. Essentially it is the same. @RheumNow #ACR22 Abstr#1072 https://t.co/OBOMz35soX https://t.co/dPdcWQmBzd
Richard Conway RichardPAConway ( View Tweet)
Soussi et al. Over last 20 years, 5-year all-cause morality decreased in RA and controls in Danish study. But to greater extent in RA, narrowing mortality gap. @RheumNow #ACR22 Abstr#0711 https://t.co/JRh37u3uGm https://t.co/bA3Y5FLcRZ
Richard Conway RichardPAConway ( View Tweet)
Have you heard of MyPROSLE (available at https://t.co/a4zlBtwaaC)? Abs 0329 details MyPROSLE's molecular characterization of individual SLE pts and it's extraction of key molecular information to support more precise therapeutic decisions. #ACR22 @RheumNow https://t.co/FslQCVvptw https://t.co/NNlgZvllPC
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
🔥ignite session🔥
❓Vessel wall MRI superior to TA-US in c-GCA❓
🔥In c-GCA vessel wall MRI examines beyond the temporal arteries -
✅more 🧠 cranial arteries, including occipital arteries and the all important 👁 orbital structures
Abst#0473
#ACR22 @RheumNow https://t.co/z8hYmqc95I
Patricia Harkins DrTrishHarkins ( View Tweet)
Carter et al. Case series showing rapid effect of anifrolumab in refractory discoid lupus and SCLE. @RheumNow #ACR22 Abstr#0974 https://t.co/Od1PXzJKQh https://t.co/Hk8mrblGMX
Richard Conway RichardPAConway ( View Tweet)
Ab2126 #ACR22 Risankizumab on Enthesitis/Dactylitis
KEEPsAKE 1&2 - RZB v PBO
1407 pts -baseline 63% enth, 28% dact, 20% both
Wk 24: 14% decr. enthesitis, 17% decr dact, 13% decr both
Mean time to resolution decreased
Results maintained through wk 52
@RheumNow https://t.co/RBubeuJoh8
Eric Dein ericdeinmd ( View Tweet)
Frey @CaoilfhionnMD @JuliePaikMD et al. Increasing duration of hold of MMF (esp >=10 days) increased response to SARS-CoV-2 vaccine. No difference in disease flare rates. @RheumNow #ACR22 Abstr#0797 https://t.co/5nxo2nLg80 https://t.co/sx1Roxngx9
Richard Conway RichardPAConway ( View Tweet)
In this prospective cohort study by Dr Jacquez, there was a statistically significant inverse assoc bet. average yearly HCQ dose and overall damage accrual 👇
Reassuring data.
☝️HCQ consistently proves to be a beneficial drug for #lupus
#ACR22 @Rheumnow ABST#0982 @rheumarhyme https://t.co/nWHS9JtEsH
sheila RHEUMarampa ( View Tweet)
Pedersen @EBRheum et al. 203 RCTs, 35 (17.2%) remained unpublished more than 30 months after completion. Cited reasons: ongoing preparation/review of paper (50%), sponsor/funder problems (40%), unimportant/negative result (20%).@RheumNow #ACR22 Abstr#0827 https://t.co/V2a48iiAcn https://t.co/FLqQhjvlOx
Richard Conway RichardPAConway ( View Tweet)
#ACR22 Abstr#0825 Can we identify predictors of deaths in patients presenting with Macrophage Activation Syndrome? A cohort study (N=43) reported MAS was mostly secondary to disease. 10/43 died. Super high Ferritin and raised Ferritin/CRP ratio were assoc with deaths @RheumNow https://t.co/JCH30pi4Vf
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
